Mirikizumab-mrkz

Brand names: Omvoh · Active ingredient: Mirikizumab

In short: OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults.

Forms & strengthsOMVOH is a clear to opalescent, colorless to slightly yellow to slightly brown solution available as: Intravenous Infusion: Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial Subcutaneous Use: Injection: 100 mg/mL solution in a single-dose …
LabelEli Lilly and Company
Label updatedAug 11, 2026

What is Mirikizumab-mrkz used for?

OMVOH is indicated for the treatment of:

moderately to severely active ulcerative colitis in adults.

moderately to severely active Crohn's disease in adults.

Mirikizumab-mrkz dosage

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with OMVOH .

Obtain liver enzymes and bilirubin levels prior to initiating treatment with OMVOH .

Complete all age-appropriate vaccinations according to current immunization guidelines .

Induction Dosage

Week 0, Week 4, and Week 8: Infuse 300 mg intravenously over at least 30 minutes .

Maintenance Dosage

Week 12 and every 4 weeks thereafter: Inject 200 mg subcutaneously (given as one injection of 200 mg or as two consecutive injections of 100 mg each) .

Induction Dosage

Week 0, Week 4, and Week 8: Infuse 900 mg intravenously over at least 90 minutes .

Maintenance Dosage

Week 12 and every 4 weeks thereafter: Inject 300 mg subcutaneously (given as two consecutive injections of 100 mg and 200 mg in any order) .

OMVOH for intravenous use is intended for administration by a healthcare provider using aseptic technique.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be a clear to opalescent, colorless to slightly yellow to slightly brown solution, and free of visible particles. Do not use OMVOH if it is cloudy or there are visible particles.

Prior to intravenous administration, determine the dose needed based on the patient's indication . For Crohn's disease, discard 45 mL of the infusion bag prior to adding vial contents. Withdraw the required amount of solution from the vial(s) using a 18 gauge to 21 gauge needle and transfer to an infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection . Do not mix with other drugs. Do not dilute or infuse through the same intravenous line with other solutions.

Table 1: Intravenous Induction Dose and Volume of Diluent Required

Indication

Intravenous Induction Dose

Number of OMVOH 300mg/15mL vials needed

Volume of

0.9% Sodium Chloride or5% Dextrose Injection

Ulcerative colitis

300 mg

1

50 mL, 100 mL, or 250 mL

Crohn's disease

900 mg

3

100 mL or 250 mL

Gently invert the infusion bag to mix the contents. Do not shake the prepared infusion bag.

Connect the intravenous administration set (infusion line) to the prepared infusion bag and prime the line.

Infuse the diluted solution intravenously over a period of at least 30 minutes for the 300 mg dose; at least 90 minutes for the 900 mg dose. If stored refrigerated, allow the diluted solution in the infusion bag to warm to room temperature prior to the start of the intravenous infusion.

At the end of the infusion, flush the line with 0.9% Sodium Chloride Injection or 5% Dextrose Injection.

Administer the flush at the same infusion rate as used for OMVOH administration. …

How to take Mirikizumab-mrkz — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Hypersensitivity Reactions

Advise patients to discontinue OMVOH and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions .

Infections

Advise patients that OMVOH may lower the ability of their immune system to fight infections and to contact their healthcare provider immediately if they develop any symptoms of infection .

Tuberculosis

Advise patients to contact their healthcare provider if they experience symptoms suggestive of TB (e.g., unexplained fever, cough, or difficulty breathing) .

Hepatotoxicity

Inform patients that OMVOH may cause liver injury. Advise patients to seek immediate medical attention if they experience symptoms suggestive of liver dysfunction (e.g., unexplained rash, nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine) .

Immunizations

Advise patients that vaccination with live vaccines is not recommended during OMVOH treatment and immediately prior to or after OMVOH treatment. …

Warnings & precautions

Do not take this medicine if: OMVOH is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients .

Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with OMVOH administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction . If a severe hypersensitivity reaction occurs, discontinue OMVOH immediately and initiate appropriate treatment.

OMVOH may increase the risk of infection .

Do not initiate treatment with OMVOH in patients with a clinically important active infection until the infection resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing OMVOH. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer OMVOH until the infection resolves.

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with OMVOH.

Do not administer OMVOH to patients with active TB infection. Initiate treatment of latent TB prior to administering OMVOH. Consider anti-TB therapy prior to initiation of OMVOH in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after OMVOH treatment.

In clinical trials, subjects were excluded if they had evidence of active TB, a past history of active TB, or were diagnosed with latent TB at screening. …

Mirikizumab-mrkz side effects

The following topics are also discussed in detail in the Warnings and Precautions section:

Hypersensitivity Reactions

Infections

Tuberculosis

Hepatotoxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Ulcerative Colitis

OMVOH was studied up to 12 weeks in subjects with moderately to severely active ulcerative colitis in a randomized, double-blind, placebo-controlled induction study (UC-1). In subjects who responded to induction therapy in UC-1, long term safety up to 52 weeks was evaluated in a randomized, double-blind, placebo-controlled maintenance study (UC-2) and a long-term extension study .

In the induction study (UC-1), 1279 subjects were enrolled of whom 958 received OMVOH 300 mg administered as an intravenous infusion at Weeks 0, 4, and 8. In the maintenance study (UC-2), 581 subjects were enrolled of whom 389 received OMVOH 200 mg administered as a subcutaneous injection every 4 weeks.

Table 2 summarizes the adverse reactions reported in at least 2% of subjects and at a higher frequency than placebo during UC-1.

a Reported in at least 2% of subjects and at a higher frequency than placebo.

b OMVOH 300 mg as an intravenous infusion at Weeks 0, 4, and 8. …

Drug interactions

Increased concentrations of cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation associated with certain diseases including Crohn's disease may suppress the formation of CYP450 enzymes. Therapeutic proteins, including mirikizumab-mrkz, that decrease the concentrations of these pro-inflammatory cytokines may increase the formation of CYP450 enzymes resulting in decreased CYP450 substrate exposure. Upon initiation or discontinuation of OMVOH in patients treated with concomitant CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP450 substrate as needed. See the prescribing information of specific CYP450 substrates.

About this medicine

Mirikizumab-mrkz is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody that is directed against the p19 subunit of IL-23 and does not bind IL-12. Mirikizumab-mrkz is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology and it is composed of two identical light chain polypeptides and two identical heavy chain polypeptides with an overall molecular weight of approximately 147 kDa.

OMVOH for intravenous infusion for ulcerative colitis and Crohn's disease

OMVOH (mirikizumab-mrkz) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution in a single-dose vial for intravenous infusion after dilution.

OMVOH injection 300 mg /15 mL vial is available in 2 formulations:

Each mL contains 20 mg of mirikizumab-mrkz, anhydrous citric acid (0.4 mg), polysorbate 80 (0.5 mg), sodium chloride (8.8 mg), sodium citrate (2.1 mg), and Water for Injection. The OMVOH solution has a pH range of 5.0 to 6.0. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 472cbe04-263e-433d-9a0f-58c1b50b715a. Read the full official label on DailyMed.